Clinical Trial Update: RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer) [Phase 4]

View source ↗

Summary

This Phase 4 trial (RADIANT) compares Radium-223 Dichloride (Xofigo) versus Enzalutamide or Abiraterone in metastatic castration-resistant prostate cancer with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Xofigo (radium-223 dichloride)
• Xtandi (enzalutamide)
• Zytiga (abiraterone acetate)

Snippet

Sponsor: Bayer | Conditions: Metastatic Castrate Resistant Prostate Cancer (mCRPC) | Phase 4 | Status: ACTIVE_NOT_RECRUITING